Clinical Trials
23 trialsNCT02106572 2026-05-22
TIM
Abnoba Gmbh
Phase 3 Terminated
NCT06026332 2026-02-17
ABLE-41
Ferring Pharmaceuticals
Terminated
NCT04412070 2025-11-21
ALU
Hopital Foch
Terminated
NCT05014139 2025-11-20
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Astellas Pharma Inc
Phase 1 Terminated
NCT06448364 2024-11-06
LTbR
Pfizer
Phase 1 Terminated
NCT04690699 2024-10-24
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
Istari Oncology, Inc.
Phase 1/2 Terminated
NCT01625260 2024-07-19
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
Phase 1/2 Terminated
NCT04688931 2024-06-06
ATLAS
UroGen Pharma Ltd.
Phase 3 Terminated
NCT06069453 2023-10-05
Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.
Fidia Farmaceutici s.p.a.
Phase NA Terminated
NCT03519256 2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2 Terminated
NCT03549650 2022-03-04
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Terminated
NCT02563561 2021-10-27
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT03498196 2020-08-24
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
Baylor College of Medicine
Phase 1/2 Terminated
NCT03719300 2020-08-19
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Anchiano Therapeutics Israel Ltd.
Phase 2 Terminated
NCT03167151 2020-07-31
PemBla
University of Oxford
Phase 1/2 Terminated
NCT02982395 2019-08-30
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
Samyang Biopharmaceuticals Corporation
Phase 3 Terminated
NCT02605863 2018-10-03
Enzalutamide for Bladder Cancer Chemoprevention
University of Rochester
Phase 2 Terminated
NCT01469221 2017-12-15
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01475266 2017-03-29
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Nippon Kayaku Co., Ltd.
Phase 2/3 Terminated
NCT01410565 2016-12-13
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01314664 2015-06-12
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
Endo Pharmaceuticals
Terminated
NCT00384891 2014-10-07
Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
Medical Enterprises Europe B.V.
Phase 3 Terminated